소화기암 시장 보고서(2025년)

Gastrointestinal (GI) cancer comprises a group of malignancies that affect the digestive organs, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers occur when abnormal cells begin to grow uncontrollably within the gastrointestinal tract. The primary objectives of GI cancer treatment are to remove or manage the cancer, alleviate associated symptoms, and enhance the patient's quality of life.

The major categories of gastrointestinal cancer include colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer, which affects the colon or rectum, is largely influenced by genetic predispositions and lifestyle factors, making it suitable for focused screening and specialized treatment approaches in GI oncology. Diagnosis is conducted using techniques such as endoscopy, biopsy, molecular diagnostics, imaging, and more. Treatment options consist of chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and other modalities. These are utilized across various settings, including hospitals, oncology centers, diagnostic labs, research institutions, and others.

The gastrointestinal cancer market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal cancer market statistics, including the gastrointestinal cancer industry global market size, regional shares, competitors with the gastrointestinal cancer market share, detailed gastrointestinal cancer market segments, market trends, opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. This gastrointestinal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastrointestinal cancer market size has grown rapidly in recent years. It will grow from $24.09 billion in 2024 to $27.05 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The expansion during the historic period was fueled by the increasing incidence of GI cancers, heightened tobacco and alcohol use, a rising elderly population, unhealthy dietary patterns, and significant progress in cancer diagnostics and treatment methods.

The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $42.45 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by the wider application of biomarker-based therapies, greater public awareness regarding early cancer detection, strengthened healthcare systems, supportive government programs for oncology care, and a rising preference for less invasive treatment techniques. Key market trends projected for this period include advancements in diagnostic technologies, breakthroughs in targeted and immunotherapies, integration of artificial intelligence in cancer management, and continued progress in precision medicine research.

The rising adoption of targeted therapies is expected to propel the growth of the gastrointestinal cancer market going forward. Targeted therapies are treatments that precisely block cancer cell growth by acting on specific molecular targets, reducing harm to normal, healthy cells. These therapies are designed to act on specific molecular pathways or genetic mutations driving a disease, especially in cancer. Unlike traditional treatments like chemotherapy, which attack both healthy and diseased cells, targeted therapies focus on the unique characteristics of a patient's condition. In the case of gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins that control tumor growth, enabling precise and effective treatment. This approach results in better outcomes with fewer side effects compared to conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II by the end of quarter one (Q1) 2023, which rose by 5% to reach 260 by the end of quarter two (Q2). Therefore, the rising adoption of targeted therapies is driving the growth of the gastrointestinal cancer market.

Major companies operating in the gastrointestinal cancer market are focused on developing advanced solutions, such as monoclonal antibody treatment, to improve patient survival rates and minimize treatment-related side effects. Monoclonal antibody treatment involves using laboratory-produced antibodies that precisely identify and attach to cancer cells, assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, which received approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first and only therapy in the European Union targeting CLDN18.2, a biomarker present in about 38% of these patients, based on positive clinical trial data from the SPOTLIGHT and GLOW studies.

In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. With this acquisition, GSK aims to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its capabilities in precision medicine to better address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).

Major players in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, and Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastrointestinal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastrointestinal Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastrointestinal cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastrointestinal cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Colorectal Cancer; Stomach Cancer; Esophageal Cancer; Pancreatic Cancer; Liver Cancer; Other Cancer Types
• 2) By Diagnostics: Endoscopy; Biopsy; Molecular Diagnostics; Imaging; Other Diagnostics
• 3) By Treatment: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery; Other Treatments
• 4) By End-User: Hospitals; Oncology Centers; Research Institutes; Diagnostic Laboratories; Other End-Users
• Subsegments:
• 1) By Colorectal Cancer: Colon Cancer; Rectal Cancer; Recurrent Colorectal Cancer; Metastatic Colorectal Cancer
• 2) By Stomach Cancer: Adenocarcinoma; Gastrointestinal Stromal Tumors (GIST); Lymphoma; Carcinoid Tumors
• 3) By Esophageal Cancer: Adenocarcinoma; Squamous Cell Carcinoma; Small Cell Carcinoma; Other Rare Esophageal Tumors
• 4) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Endocrine (Neuroendocrine) Pancreatic Tumors; Metastatic Pancreatic Cancer; Resectable Or Unresectable Tumors
• 5) By Liver Cancer: Hepatocellular Carcinoma (HCC); Intrahepatic Cholangiocarcinoma; Hepatoblastoma; Secondary (Metastatic) Liver Cancer
• 6) By Other Cancer Types: Small Intestine Cancer; Anal Cancer; Gallbladder Cancer; Gastrointestinal Carcinoid Tumor
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastrointestinal Cancer Market Characteristics

3. Gastrointestinal Cancer Market Trends And Strategies

4. Gastrointestinal Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastrointestinal Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastrointestinal Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastrointestinal Cancer Market Growth Rate Analysis
• 5.4. Global Gastrointestinal Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastrointestinal Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastrointestinal Cancer Total Addressable Market (TAM)

6. Gastrointestinal Cancer Market Segmentation

• 6.1. Global Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer
• Stomach Cancer
• Esophageal Cancer
• Pancreatic Cancer
• Liver Cancer
• Other Cancer Types
• 6.2. Global Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopy
• Biopsy
• Molecular Diagnostics
• Imaging
• Other Diagnostics
• 6.3. Global Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• Other Treatments
• 6.4. Global Gastrointestinal Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Centers
• Research Institutes
• Diagnostic Laboratories
• Other End-Users
• 6.5. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Colorectal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colon Cancer
• Rectal Cancer
• Recurrent Colorectal Cancer
• Metastatic Colorectal Cancer
• 6.6. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Stomach Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Gastrointestinal Stromal Tumors (GIST)
• Lymphoma
• Carcinoid Tumors
• 6.7. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Esophageal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Squamous Cell Carcinoma
• Small Cell Carcinoma
• Other Rare Esophageal Tumors
• 6.8. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Pancreatic Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine Pancreatic Cancer
• Endocrine (Neuroendocrine) Pancreatic Tumors
• Metastatic Pancreatic Cancer
• Resectable Or Unresectable Tumors
• 6.9. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocellular Carcinoma (HCC)
• Intrahepatic Cholangiocarcinoma
• Hepatoblastoma
• Secondary (Metastatic) Liver Cancer
• 6.10. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Intestine Cancer
• Anal Cancer
• Gallbladder Cancer
• Gastrointestinal Carcinoid Tumors

7. Gastrointestinal Cancer Market Regional And Country Analysis

• 7.1. Global Gastrointestinal Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastrointestinal Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastrointestinal Cancer Market

• 8.1. Asia-Pacific Gastrointestinal Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastrointestinal Cancer Market

• 9.1. China Gastrointestinal Cancer Market Overview
• 9.2. China Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastrointestinal Cancer Market

• 10.1. India Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastrointestinal Cancer Market

• 11.1. Japan Gastrointestinal Cancer Market Overview
• 11.2. Japan Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastrointestinal Cancer Market

• 12.1. Australia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastrointestinal Cancer Market

• 13.1. Indonesia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastrointestinal Cancer Market

• 14.1. South Korea Gastrointestinal Cancer Market Overview
• 14.2. South Korea Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastrointestinal Cancer Market

• 15.1. Western Europe Gastrointestinal Cancer Market Overview
• 15.2. Western Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastrointestinal Cancer Market

• 16.1. UK Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastrointestinal Cancer Market

• 17.1. Germany Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastrointestinal Cancer Market

• 18.1. France Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastrointestinal Cancer Market

• 19.1. Italy Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastrointestinal Cancer Market

• 20.1. Spain Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastrointestinal Cancer Market

• 21.1. Eastern Europe Gastrointestinal Cancer Market Overview
• 21.2. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastrointestinal Cancer Market

• 22.1. Russia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastrointestinal Cancer Market

• 23.1. North America Gastrointestinal Cancer Market Overview
• 23.2. North America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastrointestinal Cancer Market

• 24.1. USA Gastrointestinal Cancer Market Overview
• 24.2. USA Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastrointestinal Cancer Market

• 25.1. Canada Gastrointestinal Cancer Market Overview
• 25.2. Canada Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastrointestinal Cancer Market

• 26.1. South America Gastrointestinal Cancer Market Overview
• 26.2. South America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastrointestinal Cancer Market

• 27.1. Brazil Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastrointestinal Cancer Market

• 28.1. Middle East Gastrointestinal Cancer Market Overview
• 28.2. Middle East Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastrointestinal Cancer Market

• 29.1. Africa Gastrointestinal Cancer Market Overview
• 29.2. Africa Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastrointestinal Cancer Market Competitive Landscape And Company Profiles

• 30.1. Gastrointestinal Cancer Market Competitive Landscape
• 30.2. Gastrointestinal Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Gastrointestinal Cancer Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Parexel International Corporation
• 31.10. Ipsen Biopharmaceuticals Inc.
• 31.11. Exelixis Inc.
• 31.12. BeiGene Ltd.
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Zai Lab Limited
• 31.15. Taiho Pharmaceutical Co. Ltd.

32. Global Gastrointestinal Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastrointestinal Cancer Market

34. Recent Developments In The Gastrointestinal Cancer Market

35. Gastrointestinal Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Gastrointestinal Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastrointestinal Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastrointestinal Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer